Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to GT199200050ApriorityCriticalpatent/GT199200050A/en
Publication of GT199200050ApublicationCriticalpatent/GT199200050A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
SE RERFIERE A UN ANTICUERPO MONOCLONAL O UN FRAGMENTO DEL MISMO CAPAZ DE UNIRSE POR LOMENOS A UN EPITOPO DE LA SUB UNIDADALPHADEL RECPTOR DE ALTA AFINIDAD FC DE LA IGE, SE GREGANDO LAS CELULAS DE HIBRIDOMA DICHO ANTICUERPO MONOCLO NAL UN PROCESO PARA LA PREPARACION DE DICHA CELULA DE HIBRIDOMA Y PARA LA PREPARACION DE DICHO ANTICUERPO MONOCLONAL OFRAGMENTO DEL MISMO, COMPOSICIONES FARMACEUTICAS CONTENIENDODICHO ANTICUERPO O FRAGMENTO DEL MISMO Y EL EMPLEO DE DICHO ANTICUERPO O FRAGMENTO DEL MISMO PARA FINES TERAPEUTICOS, DIAGNOSIS Y PURIFICACION.IT REFERS TO A MONOCLONAL ANTIBODY OR A FRAGMENT OF THE SAME CAPACITY TO JOIN BY LOMENOS TO AN EPITOPE OF THE SUB UNIT PHOTEL OF THE HIGH AFFINITY RECEIVER OF THE IGE, CALLING THE CELLS OF A NIBRIDOMA CALLED A NATIONAL ANTIBODY, NATIONAL OF HYBRIDOMA AND FOR THE PREPARATION OF SUCH MONOCLONAL ANTIBODY OFRAGMENT OF THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH ANTIBODY OR FRAGMENT OF THE SAME, AND THE USE OF SUCH ANTIBODY OR FRAGMENT OF THE SAME PURPOSE FOR SOME DURATION.
GT199200050A1992-08-111992-08-11
MONOCLONAL ANTIBODY TO THE ALPHA SUB-UNIT OF THE HUMAN RECEPTOR AND ITS USES
GT199200050A
(en)
IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.
HYBRID CELL LINE FOR THE PRODUCTION OF COMPLEMENT-FIXING MONOCLONAL ANTIBODIES ANTI-HUMAN SUPPRESSOR T-CELLS; ANTIBODY AND METHODS OF PRODUCTION; DIAGNOSTIC AND THERAPEUTIC USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE ANTIBODIES.
Conjugation between cloned human NK cells (H7. 8) and K562/MOLT4 tumor cell systems: saturability, binding parameters, and population distribution of conjugates